Raymond James & Associates’s Precision BioSciences DTIL Stock Holding History

Raymond James & Associates’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,387	Closed	-$480K	–	4176
2021 Q3	$480K	Sell	1,387 -124	-8%	-$42K	﹤0.01%	3095
2021 Q2	$568K	Buy	+1,511	New	+$454K	﹤0.01%	2994
2020 Q4	–	Sell	-615	Closed	-$114K	–	3795
2020 Q3	$114K	Buy	+615	New	+$122K	﹤0.01%	3360

Other funds holding DTIL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Raymond James & Associates's DTIL Position: Q4 2021 in Review

Raymond James & Associates sold out of Precision BioSciences (DTIL) in Q4 2021, closing a stake of 1,387 shares — an estimated $480K sold.

Raymond James & Associates first reported a position in DTIL in Q3 2020 and held it in 3 quarters. The position peaked at $568K in Q2 2021. 134 funds tracked by Wall St. Rank hold DTIL as of Q4 2021.

Raymond James & Associates reported no remaining Precision BioSciences position as of Q4 2021 after selling out during the quarter.
Raymond James & Associates sold 1,387 Precision BioSciences shares in Q4 2021, an estimated $480K.
Raymond James & Associates first reported a position in Precision BioSciences in Q3 2020 and held it in 3 quarters.
Raymond James & Associates's Precision BioSciences position peaked at $568K in Q2 2021.
134 funds tracked by Wall St. Rank held Precision BioSciences as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.